23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Myriad Genetics, Inc. › 2025-2026

Myriad Genetics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Myriad Genetics, Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Ballot items
  • 227Asset managers, any item
  • 1,773Fund votes
  • June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 7 items on Myriad Genetics, Inc.’s Form 8-K, filed June 4, 2026: 3 approved · 4 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Myriad Genetics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Myriad Genetics, Inc.

These tallies are Myriad Genetics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Myriad Genetics, Inc. — official shareholder meeting results, meeting held June 4, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Paul M. Bisaro 61,842,900637,15623,264 --15,255,311 99%Passed (calculated)—
Elect Director: Rashmi Kumar 60,399,6332,071,37532,312 --15,255,311 97%Passed (calculated)—
Elect Director: Lee N. Newcomer, M.D 61,576,936894,83731,547 --15,255,311 99%Passed (calculated)—
2. Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2026 76,302,5951,391,17264,864 ---- 98%Approved—
3. Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement 59,356,7103,098,96647,644 --15,255,311 95%Approved—
4. Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan 61,812,338650,74140,241 --15,255,311 99%Approved—
5. Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan 59,389,1933,066,08748,040 --15,255,311 95%Passed (calculated)—

Source: Myriad Genetics, Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.

How asset managers voted at the Myriad Genetics, Inc. 2025-2026 meeting

227 asset managers disclosed a vote on at least one Myriad Genetics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Lee N. Newcomer, M.D

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 61,576,936AGAINST: 894,837
Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: Election of three Class III Directors to serve until the 2029 Annual Meeting of Stockholders: Lee N. Newcomer, M.D.

Myriad Genetics, Inc.’s own tally for this item (“Elect Director: Lee N. Newcomer, M.D”): 61,576,936 for, 894,837 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 25,734,464 for, 79,551 against.

FOR
FOR: 25,734,464AGAINST: 79,551
Largest asset managers voting on “Election of three Class III Directors to serve until the 2029 Annual Meeting of Stockholders: Lee N. Newcomer,” at Myriad Genetics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,665,8098,364 00For
BlackRock4,269,3040 00For
Fidelity2,725,1010 00For
State Street2,399,7583,124 00For
Charles Schwab1,802,3970 00For
Federated Hermes1,600,2230 00For
Aberdeen1,110,4040 00For
TIAA792,4580 00For
Goldman Sachs618,5700 00For
Nationwide371,3950 00For
Dimensional262,6730 00For
Columbia Threadneedle260,4690 00For
Invesco235,2990 00For
Equitable134,26267,580 00Mixed
AQR185,6860 00For
Northern Trust163,4110 00For
Voya154,9010 00For
JPMorgan154,5590 00For
QUANTITATIVE MASTER SERIES LLC150,7780 00For
GuideStone149,2560 00For
Lincoln Financial133,1510 00For
Northern Lights Fund Trust IV115,7240 00For
MFS115,2010 00For
Harbor ETF Trust87,6860 00For
American Century85,6150 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Elect Director: Paul M. Bisaro

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 61,842,900AGAINST: 637,156
Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: Election of three Class III Directors to serve until the 2029 Annual Meeting of Stockholders: Paul M. Bisaro

Myriad Genetics, Inc.’s own tally for this item (“Elect Director: Paul M. Bisaro”): 61,842,900 for, 637,156 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 25,734,465 for, 79,550 against.

FOR
FOR: 25,734,465AGAINST: 79,550
Largest asset managers voting on “Election of three Class III Directors to serve until the 2029 Annual Meeting of Stockholders: Paul M. Bisaro” at Myriad Genetics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,665,8108,363 00For
BlackRock4,269,3040 00For
Fidelity2,725,1010 00For
State Street2,399,7583,124 00For
Charles Schwab1,802,3970 00For
Federated Hermes1,600,2230 00For
Aberdeen1,110,4040 00For
TIAA792,4580 00For
Goldman Sachs618,5700 00For
Nationwide371,3950 00For
Dimensional262,6730 00For
Columbia Threadneedle260,4690 00For
Invesco235,2990 00For
Equitable134,26267,580 00Mixed
AQR185,6860 00For
Northern Trust163,4110 00For
Voya154,9010 00For
JPMorgan154,5590 00For
QUANTITATIVE MASTER SERIES LLC150,7780 00For
GuideStone149,2560 00For
Lincoln Financial133,1510 00For
Northern Lights Fund Trust IV115,7240 00For
MFS115,2010 00For
Harbor ETF Trust87,6860 00For
American Century85,6150 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Elect Director: Rashmi Kumar

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 60,399,633AGAINST: 2,071,375
Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: Election of three Class III Directors to serve until the 2029 Annual Meeting of Stockholders: Rashmi Kumar

Myriad Genetics, Inc.’s own tally for this item (“Elect Director: Rashmi Kumar”): 60,399,633 for, 2,071,375 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 25,563,365 for, 250,650 against.

FOR
FOR: 25,563,365AGAINST: 250,650
Largest asset managers voting on “Election of three Class III Directors to serve until the 2029 Annual Meeting of Stockholders: Rashmi Kumar” at Myriad Genetics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,665,8088,365 00For
BlackRock4,269,3040 00For
Fidelity2,725,1010 00For
State Street2,399,7583,124 00For
Charles Schwab1,802,3970 00For
Federated Hermes1,600,2230 00For
Aberdeen1,110,4040 00For
TIAA792,4580 00For
Goldman Sachs618,5700 00For
Nationwide371,3950 00For
Dimensional262,6730 00For
Columbia Threadneedle260,4690 00For
Invesco235,2990 00For
Equitable134,26267,580 00Mixed
AQR185,6860 00For
Northern Trust0163,411 00Against
Voya154,9010 00For
JPMorgan154,5590 00For
QUANTITATIVE MASTER SERIES LLC150,7780 00For
GuideStone149,2560 00For
Lincoln Financial133,1510 00For
Northern Lights Fund Trust IV115,7240 00For
MFS115,2010 00For
Harbor ETF Trust87,6860 00For
American Century85,6150 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan

Official resultCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%
FOR: 61,812,338AGAINST: 650,741
Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: TO APPROVE THE PROPOSED AMENDMENT TO THE AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN.

Myriad Genetics, Inc.’s own tally for this item (“4. Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan”): 61,812,338 for, 650,741 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders voted to approve the proposed amendment to the Purchase Plan to increase the aggregate number of shares of common stock available for issuance under the Purchase Plan by an additional 4,000,000 shares.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 25,817,122 for, 2 against.

FOR
FOR: 25,817,122AGAINST: 2
Largest asset managers voting on “TO APPROVE THE PROPOSED AMENDMENT TO THE AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN.” at Myriad Genetics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,674,1702 00For
BlackRock4,269,3040 00For
Fidelity2,725,1010 00For
State Street2,402,8820 00For
Charles Schwab1,802,3970 00For
Federated Hermes1,600,2230 00For
Aberdeen1,110,4040 00For
TIAA792,4580 00For
Goldman Sachs618,5700 00For
Nationwide371,3950 00For
Dimensional262,6730 00For
Columbia Threadneedle260,4690 00For
Invesco235,2990 00For
Equitable201,8420 00For
AQR185,6860 00For
Northern Trust163,4110 00For
Voya154,9010 00For
JPMorgan154,5590 00For
QUANTITATIVE MASTER SERIES LLC150,7780 00For
GuideStone149,2560 00For
Lincoln Financial133,1510 00For
Northern Lights Fund Trust IV115,7240 00For
MFS115,2010 00For
Harbor ETF Trust87,6860 00For
American Century85,6150 00For

Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).

Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan

Calculated outcomeCOMPENSATIONPassed (calculated)

95% Majority: yes · of votes cast

FOR 95%
FOR: 59,389,193AGAINST: 3,066,087
Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: TO APPROVE THE PROPOSED 2026 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN.

Myriad Genetics, Inc.’s own tally for this item (“5. Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan”): 59,389,193 for, 3,066,087 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 24,031,486 for, 1,768,615 against.

FOR
FOR: 24,031,486AGAINST: 1,768,615
Largest asset managers voting on “TO APPROVE THE PROPOSED 2026 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN.” at Myriad Genetics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,665,8028,371 00For
BlackRock4,269,3040 00For
Fidelity2,725,1010 00For
State Street2,399,6633,219 00For
Charles Schwab1,802,3970 00For
Federated Hermes01,600,223 00Against
Aberdeen1,110,4040 00For
TIAA792,4580 00For
Goldman Sachs618,5700 00For
Nationwide371,3950 00For
Dimensional262,6730 00For
Columbia Threadneedle260,4690 00For
Invesco235,2990 00For
Equitable201,8420 00For
AQR185,6860 00For
Northern Trust163,4110 00For
Voya154,9010 00For
JPMorgan154,5590 00For
QUANTITATIVE MASTER SERIES LLC150,7780 00For
GuideStone149,2560 00For
Lincoln Financial133,1510 00For
Northern Lights Fund Trust IV115,7240 00For
MFS115,2010 00For
Harbor ETF Trust87,6860 00For
American Century085,615 00Against

Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).

Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 59,356,710AGAINST: 3,098,966

Prior year: 92.1% for (June 5, 2025 meeting) ▲ 3.0 pts

Details: description as filed, official tally, votes by 225 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

Myriad Genetics, Inc.’s own tally for this item (“3. Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement”): 59,356,710 for, 3,098,966 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement, was approved by stockholders.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Myriad Genetics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Say on Pay” (2 managers, 107 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 65 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY ” at Myriad Genetics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,674,16210 00For
BlackRock4,269,3040 00For
Fidelity2,725,1010 00For
State Street2,402,8820 00For
Charles Schwab1,802,3970 00For
Federated Hermes1,600,2230 00For
Aberdeen01,110,404 00Against
TIAA792,4580 00For
Goldman Sachs618,5700 00For
Nationwide371,3950 00For
Dimensional262,6730 00For
Columbia Threadneedle0260,469 00Against
Invesco235,2990 00For
Equitable201,8420 00For
AQR185,6860 00For
Northern Trust163,4110 00For
Voya154,9010 00For
JPMorgan154,5590 00For
QUANTITATIVE MASTER SERIES LLC150,7780 00For
GuideStone149,2560 00For
Lincoln Financial133,1510 00For
Northern Lights Fund Trust IV115,7240 00For
MFS0115,201 00Against
Harbor ETF Trust87,6860 00For
American Century85,6150 00For

Fund voting reports, all 65 managers: 24,320,242 for, 1,493,771 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 183 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY ” at Myriad Genetics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
GLENVIEW CAPITAL MANAGEMENT, LLC5,411,9780 00For
State Street4,298,7013,130 00For
DE Shaw4,296,4920 00For
BlackRock4,190,341817 00For
GEODE CAPITAL MANAGEMENT, LLC2,322,9840 00For
ACADIAN ASSET MANAGEMENT LLC1,826,4770 00For
Charles Schwab1,802,6690 00For
Federated Hermes1,778,9670 00For
Invesco1,614,8290 00For
Vestal Point Capital, LP1,309,1480 00For
JACOBS LEVY EQUITY MANAGEMENT, INC1,251,8520 00For
AQR1,154,1150 00For
Aberdeen01,110,404 00Against
Fisher Asset Management, LLC915,0700 00For
Vanguard884,8200 00For
Two Sigma850,3260 00For
Nuveen820,3600 00For
MARSHALL WACE, LLP813,0140 00For
Northern Trust789,2000 00For
Fidelity587,1650 00For
Goldman Sachs501,1510 00For
Connor, Clark & Lunn Investment Management Ltd.448,2010 00For
WELLS FARGO CLEARING SERVICES, LLC438,3380 00For
STATE OF WISCONSIN INVESTMENT BOARD392,9450 00For
MELLON INVESTMENTS Corp356,6650 00For

Institutional-manager reports, all 183 managers: 43,368,828 for, 2,169,081 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 76,302,595AGAINST: 1,391,172

Prior year: 95.6% for (June 5, 2025 meeting) ▲ 2.6 pts

Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.

Myriad Genetics, Inc.’s own tally for this item (“2. Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2026”): 76,302,595 for, 1,391,172 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was approved by stockholders.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 24,699,410 for, 1,114,604 against.

FOR
FOR: 24,699,410AGAINST: 1,114,604
Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR” at Myriad Genetics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,670,0684,105 00For
BlackRock4,269,3040 00For
Fidelity2,725,1010 00For
State Street2,402,78795 00For
Charles Schwab1,802,3970 00For
Federated Hermes1,600,2230 00For
Aberdeen01,110,404 00Against
TIAA792,4580 00For
Goldman Sachs618,5700 00For
Nationwide371,3950 00For
Dimensional262,6730 00For
Columbia Threadneedle260,4690 00For
Invesco235,2990 00For
Equitable201,8420 00For
AQR185,6860 00For
Northern Trust163,4110 00For
Voya154,9010 00For
JPMorgan154,5590 00For
QUANTITATIVE MASTER SERIES LLC150,7780 00For
GuideStone149,2560 00For
Lincoln Financial133,1510 00For
Northern Lights Fund Trust IV115,7240 00For
MFS115,2010 00For
Harbor ETF Trust87,6860 00For
American Century85,6150 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Largest Myriad Genetics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 94,448,210 shares outstanding at the time of that meeting.

Fund voting reports: top Myriad Genetics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 7.07%
2BlackRock 4.52%
3Fidelity 2.89%
4State Street 2.54%
5Charles Schwab 1.91%
6Federated Hermes 1.69%
7Aberdeen 1.18%
8TIAA 0.84%
9Goldman Sachs 0.65%
10Nationwide 0.39%
Institutional-manager reports: top Myriad Genetics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS…”, 2025-2026
#Asset manager % of shares outstanding
1GLENVIEW CAPITAL MANAGEMENT, LLC 5.73%
2State Street 4.55%
3DE Shaw 4.55%
4BlackRock 4.44%
5GEODE CAPITAL MANAGEMENT, LLC 2.46%
6ACADIAN ASSET MANAGEMENT LLC 1.93%
7Charles Schwab 1.91%
8Federated Hermes 1.88%
9Invesco 1.71%
10Vestal Point Capital, LP 1.39%

Reported Myriad Genetics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Myriad Genetics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock Portfolio Management LLC9,900,937 10.48%Schedule 13G, filed September 4, 2026
BlackRock8,889,644 9.41%Form 13F, quarter ended March 31, 2026
Vanguard Group8,225,371 8.71%Form 13F, quarter ended March 31, 2026
Millennium Management6,668,817 7.06%Form 13F, quarter ended March 31, 2026
D.E. Shaw4,499,724 4.76%Form 13F, quarter ended March 31, 2026
State Street4,424,027 4.68%Form 13F, quarter ended March 31, 2026
Morgan Stanley3,607,789 3.82%Form 13F, quarter ended March 31, 2026
Goldman Sachs2,366,092 2.51%Form 13F, quarter ended March 31, 2026
Geode Capital2,319,379 2.46%Form 13F, quarter ended March 31, 2026
Charles Schwab1,801,478 1.91%Form 13F, quarter ended March 31, 2026

Percentages above are of 94,448,210 shares outstanding, as reported by Myriad Genetics, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Myriad Genetics, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 227 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 1,773 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS… — Myriad Genetics, Inc.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Myriad Genetics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Myriad Genetics, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Myriad Genetics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Myriad Genetics (MYGN) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/myriad-genetics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.